Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
ApexOnco Front Page
Recent articles
The company drops the anti-CD19 x 4-1BB project englumafusp alfa.
Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.
On a wing and a prayer AbbVie takes livmoniplimab into phase 3.
The end of three licensed assets sees Takeda take a step back from autologous cell therapy.
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.
Rusfertide’s big readout will now not come until 2025.
A third discontinuation leaves one anti-FAP project in Roche’s clinical pipeline.